Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584160 | 0.88 | RORC (0.38) | SMYD3ALDH1A1TMIGD3ADORA1 | |
| SCHEMBL3589533 | 0.83 | CXCR3 (0.35) | CNR2 | |
| SCHEMBL3594582 | 0.81 | RHOC (0.39) | SMYD3ALDH1A1 | |
| SCHEMBL13031316 | 0.80 | PTGS1 (0.39) | SMYD3PTGS1ALDH1A1PTGS2 | |
| SCHEMBL3586714 | 0.79 | CXCR3 (0.49) | — | |
| SCHEMBL3587544 | 0.78 | CXCR3 (0.37) | — | |
| SCHEMBL3579798 | 0.78 | CXCR3 (0.37) | — | |
| SCHEMBL3591383 | 0.78 | ALDH1A1 (0.37) | CNR2ALDH1A1 | |
| SCHEMBL3588162 | 0.77 | PTGS1 (0.41) | CNR2PTGS1PTGS2CNR1 | |
| SCHEMBL3585746 | 0.75 | CPT1A (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | CNR2 120/4885SMYD3 4784/4885PTGS1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.